IL1A and Ito hypomelanosis: IL-1α mis-regulation can, however, lead to inflammatory disease [84,85] and, on the basis of this, Gresnigt et al. (2016) hypothesised that inhibition of IL-1 signalling via an IL-1 receptor antagonist (IL-1Ra, Anakinra) could disrupt this vicious cycle of hypoxia-inflammation during IPA and potentially minimise disease.